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Abstract
A significant number of children undergo maternal exposure to antidepressants and they often present low birth weight.
Therefore, it is important to understand how selective serotonin reuptake inhibitors (SSRIs) affect the development of the
hypothalamus, the key center for metabolism regulation. In this study we investigated the proliferative actions of fluoxetine
in fetal hypothalamic neuroprogenitor cells and demonstrate that fluoxetine induces the proliferation of these cells, as
shown by increased neurospheres size and number of proliferative cells (Ki-67+ cells). Moreover, fluoxetine inhibits the
differentiation of hypothalamic neuroprogenitor cells, as demonstrated by decreased number of mature neurons (Neu-N+
cells) and increased number of undifferentiated cells (SOX-2+ cells). Additionally, fluoxetine-induced proliferation and
maintenance of hypothalamic neuroprogenitor cells leads to changes in the mRNA levels of appetite regulator
neuropeptides, including Neuropeptide Y (NPY) and Cocaine-and-Amphetamine-Regulated-Transcript (CART). This study
provides the first evidence that SSRIs affect the development of hypothalamic neuroprogenitor cells in vitro with
consequent alterations on appetite neuropeptides.
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Introduction
Food intake and body weight are centrally regulated by the
hypothalamus, where arcuate nucleus (ARC) neurons sense and
integrate peripheral signals of nutrition to downstream circuits
[1,2]. ARC neurons are divided in two populations acting together
to regulate appetite: the orexigenic NPY/AgRP (Neuropeptide Y/
Agouti-Related Protein) neurons and the anorexigenic POMC/CART
(Pro-OpioMelanocortin/Cocaine-and-Amphetamine-Regulated-
Transcript) neurons.
Adult hypothalamic neurogenesis occurs at low rates in rodents
but it is essential for body weight and feeding regulation [3,4].
During the embryonic period, hypothalamic neuronal precursors
are generated between days E10.5 and E14.5 [5,6] and persist
until adulthood [7]. In accordance, neuroprogenitor cells can be
isolated from fetal and adult hypothalamus and these cells express
neuropeptides important for the regulation of feeding [8].
Proliferation of hypothalamic neuroprogenitor cells during the
perinatal period is influenced by maternal nutrition and hormones
availability in mice [9,10]. Notably, this will result in body weight
and appetite defects in newborns that persist after weaning [11].
Moreover, these feeding alterations indicate a possible change of
neuropeptides levels in hypothalamic cells. Based on these studies
we can hypothesize that any molecule affecting hypothalamic cell
proliferation during the neurodevelopment period can modify the
programming of hypothalamic satiety pathways leading to
persistent changes in newborns homeostasis.
Selective serotonin reuptake inhibitors (SSRIs) are antidepres-
sant drugs also known for their neurogenic effect in perinatal
hippocampal and cerebellar neuroprogenitor cells [12,13]. Addi-
tionally, SSRIs obtained from maternal lactation have proven to
restore hippocampal neurogenesis in stressed rat offspring [14].
Nevertheless, the potential proliferative effect of SSRI in the
perinatal hypothalamus is unknown and requires investigation
since SSRIs are the drug of choice for treating depressed pregnant
and postpartum women [15]. In fact, there is a 10–16%
prevalence of depression during pregnancy and 25% of depressed
women continue antidepressant use during pregnancy [16,17]. As
most SSRIs reach the fetus via the placenta and are detectable in
breast milk [18,19] a significant number of children are exposed to
SSRIs during critical phases of hypothalamic neurodevelopment.
Accordingly, it has been reported that maternal exposure to SSRIs
results in low birth weight and modifications of the hypothalamic-
pituitary-adrenal axis of human and rodent newborns
[20,21,22,23].
Therefore, in this study we investigated whether the SSRI
fluoxetine alters the proliferation and differentiation of rat
embryonic hypothalamic neuroprogenitor cells. Moreover, using
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an in vitro model previously described by our group [8], we
evaluated the effect of fluoxetine in the expression levels of
hypothalamic neuropeptides that regulate food intake, including
orexigenic (NPY and AgRP) and anorexigenic (POMC and
CART) neuropeptides.
Materials and Methods
Ethics statement
All experimental procedures were performed in accordance with
the European Union Directive 86/609/EEC for the care and use of
laboratory animals. In addition, animals were housed in a licensed
animal facility (international Animal Welfare Assurance number
520.000.000.2006) and the CNC animal experimentation board
approved the utilization of animals for this project. Moreover,
people working with animals have received appropriate education
(FELASA course) as required by the Portuguese authorities.
Embryonic hypothalamic neurospheres culture
Hypothalamic neuroprogenitor cells were isolated and cultured
as floating neurospheres as previously described [8]. Briefly,
hypothalamic tissue dissected from rat embryos (E18-19) were
mechanically dissociated by means of a Pasteur pipette. Cells were
suspended in DMEM-F12/Glutamax supplemented with growth
factors (10 ng/ml fibroblast growth factor-2 and 10 ng/ml
epidermal growth factor), 100 U/ml penicillin, 100 mg/ml strep-
tomycin and 1% B27 supplement (all from Gibco). Every seven
days of culture, neurospheres were dissociated through a P200
pipette and re-suspended in fresh DMEM-F12/Glutamax medium
with growth factors, corresponding to one passage (P).
Differentiation of hypothalamic neuroprogenitor cells
After 6–7 days in culture, neurospheres were dissociated and
plated in Poly-D-Lysine coated culture plates as previously
described [8]. To obtain differentiated hypothalamic neural
cultures, the plated neurospheres were allowed to differentiate
for 18 days in Neurobasal medium with 500 mM L-Glutamine, 2%
B27 supplement, 100 U/ml penicillin and 100 mg/ml streptomy-
cin (all from Gibco), with no growth factors. After 18 days in
culture, differentiated hypothalamic neural cultures were used for
immunocytochemistry or RNA extraction.
Materials
Fluoxetine, Cytosine Arabinoside (AraC) and tyrosine kinases
(Trk) receptor inhibitor K252a were purchased from Sigma-
Aldrich.
Drug treatments
A recent rodent study showed that about 80% of plasma
fluoxetine is transferred to the pup after maternal injection, with
high levels of fluoxetine being detected in the pup brain [24]. For
this study, hypothalamic neuroprogenitor cells were incubated
with fluoxetine 1 mM (Sigma); this corresponds to the plasma
concentration of fluoxetine in rat pups after maternal exposure to
fluoxetine (12 mg/kg) [24]. Additionally, it was described that
1 mM fluoxetine leads to a maximal increase in proliferation
hippocampal and cerebellar neural stem cells cultures [12,13].
Hypothalamic neurospheres were cultured in the presence of
fluoxetine (1 mM); treatment with fluoxetine started 3 days after
isolation of hypothalamic neuroprogenitor cells. Control hypotha-
lamic neurospheres were cultured in the absence of fluoxetine.
To investigate the proliferative effects of fluoxetine and
contribution of neurotrophins to the fluoxetine-induced prolifer-
ation, control and fluoxetine P3 hypothalamic neurospheres were
incubated with the proliferation inhibitor AraC (10 mM) or the
Trk receptor inhibitor K252a (200 nM) during the last 24 hours
before RNA collection or plating.
Hypothalamic neuroprogenitor cultures were allowed to differ-
entiate in the presence of fluoxetine (1 mM). Treatment with
fluoxetine started 2 days after plating of hypothalamic neuro-
spheres. Incubation with Trk receptor inhibitor K252a (200 nM)
occurred during the last 24 hours before RNA collection or
fixation. Control hypothalamic neurospheres differentiated in the
absence of fluoxetine.
Immunocytochemistry of hypothalamic neurospheres
Twenty-four hours after incubation with the inhibitors, P3
hypothalamic neurospheres were plated in Poly-D-Lysine coated
12-well culture plates and kept in culture for 1 day with fresh
medium (DMEM-F12/Glutamax supplemented with growth
factors) before fixation.
P3 hypothalamic neurospheres and differentiated hypothalamic
neuroprogenitor cultures were fixed with 4% paraformaldehyde
(Sigma) and permeabilized with 1% Triton X-100 (Sigma)
followed by one hour blocking with 3% BSA (Sigma) and
incubation with the primary antibody overnight at 4uC. There-
after, the incubation with the secondary antibody was performed
for one hour at room temperature. Nuclei were stained with 496-
diamidino-2-phenylindoline, DAPI (1:5000, Applichem).The pri-
mary antibodies used were: mouse anti-Ki-67 (1:50; NovoCastra),
mouse anti-Neu-N (1:500, Chemicon) and mouse anti-SOX-2
(1:200, R&D Systems). The secondary antibodies used were: goat
anti-mouse Alexa Fluor 594 and goat anti-mouse Alexa Fluor 488
(1:200, Invitrogen).
Quantification of cell proliferation and differentiation by
immunocytochemistry
To investigate the effect of fluoxetine in the proliferation and
differentiation of hypothalamic neuroprogenitor cells, the percent-
age of Ki-67, Neu-N and SOX-2 positive cells was calculated in P3
hypothalamic neurospheres and differentiated hypothalamic neu-
roprogenitor cultures. Fluorescence images were recorded in the
monolayer formed at the neurospheres periphery (Ki-67) or in the
center of the neurospheres (Neu-N and SOX-2) using a confocal
microscope (LSM 510 Meta; Zeiss). The percentage of Ki-67, Neu-
N and SOX-2 positive cells was calculated in ten independent
microscopic fields and normalized to total number of nuclei with
DAPI staining (approximately 80–120 nuclei per microscopic field).
Data are shown as percentage of control. The procedure was
performed for four independent culture preparations.
Hypothalamic neurospheres size evaluation
The size of control and fluoxetine-treated neurospheres was
evaluated immediately before the next passage, using the
Axiovision software (Zeiss) to determine their diameter. The
neurospheres diameters oscillated between 50 and 250 mm and
this interval was divided into four subintervals (,90 mm, 90–
150 mm, 150–210 mm,.210 mm), to obtain the size distribution of
hypothalamic neurospheres. Size distribution was determined as
percentage of total number of neurospheres evaluated for each
treatment. The procedure was performed for four independent
culture preparations.
Isolation of total RNA from hypothalamic neurospheres
and cDNA synthesis
Hypothalamic neurospheres were collected by centrifugation
and immediately frozen in dry ice as described before [8]. Samples
Fluoxetine & Hypothalamic Neuroprogenitor Cells
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were kept at 280uC until RNA extraction. Total RNA was
extracted from P0 (1 week), P1 (2 weeks), P2 (3 weeks), P3 (4 weeks)
and P4 (5 weeks) hypothalamic neurospheres, and differentiated
hypothalamic neuroprogenitor cultures using the RNeasy Mini Kit
(QIAGEN) according to the manufacturer’s protocol for animal
cells. Total amount of RNA was quantified by optical density (OD)
measurements using a ND-1000 Nanodrop Spectrophotometer
(Thermo Scientific) and the purity was evaluated by measuring the
ratio of OD at 260 and 280 nm. In addition, RNA quality was
assessed by gel electrophoresis. Prior to cDNA conversion, samples
were treated with RNase-free DNAse (QIAGEN) to eliminate any
contamination with genomic DNA. cDNA was obtained from the
conversion of 1 mg of total RNA using the iScript cDNA Synthesis
Kit (Bio-Rad) according to the manufacturer’s instructions and
stored at 220uC.
PCR for evaluation of serotonergic markers
Each PCR reaction contained 50 ng of template cDNA, 0.2 ml
of Phusion Polymerase (Finnzymes), 200 mM dNTPs (Thermo-
Scientific) and 0.5 mM of reverse and forward primers, to a final
volume of 20 ml. Primers sequences for tryptophan hidroxylase
type 2 (TPH2), serotonin receptor type 5-HT1A and serotonin pre-
synaptic transporter (SERT) were previously described by others
[25,26]. PCR was performed in a thermal cycler and the thermal
conditions were as follow: 98uC for 30 sec; 35 cycles of 98uC for
10 sec, 64uC for 30 sec and 72uC for 15 sec; and 72uC for 10 min.
Total RNA extracted from adult rat brain was used as positive
control. PCR runs with RNA samples (no RT samples) and with
no polymerase served as negative controls. PCR products were run
in a 1.5% agarose gel and visualized in a Molecular Imager
GelDoc (Bio-Rad) to confirm their size and specificity of PCR
reaction.
Quantitative real time PCR (qRT-PCR)
Quantitative PCR was performed in an iQ5 thermocycler (Bio-
Rad) using 96-well microtitre plates and the QuantiTect SYBR
Green PCR Master Mix (QIAGEN) as described before [24]. The
cDNA was diluted 1006 times in RNase-free water. The primers
for the target genes (rat NPY, AgRP, POMC, CART and BDNF)
and the reference gene (rat HPRT) were pre-designed and
validated by QIAGEN (QuantiTect Primers, QIAGEN). A master
mix was prepared for each primer set containing the appropriate
volume of 26 QuantiTect SYBR Green PCR Master Mix and
106QuantiTect Primer (both from QIAGEN). For each reaction,
18 ml of master mix were added to 2 ml of template cDNA. All
reactions were performed in duplicate (two cDNA reactions per
RNA sample). The reactions were performed according to the
manufacturer’s recommendations: 95uC for 15 min. followed by
40 cycles of 94uC for 15 sec, 55uC for 30 sec and 72uC for 30 sec.
The melting curve protocol started immediately after amplifica-
tion. Additionally, the PCR products were run in a 2% agarose gel
to confirm their size. PCR runs with RNA samples (no RT
samples) served as negative controls. The amplification efficiency
for each gene and the threshold values for threshold cycle
determination (Ct) were determined automatically by the iQ5
Optical System Software (Bio-Rad).
Relative mRNA quantification was performed using the DCt
method for genes with the same amplification efficiency. The
mRNA quantification of different neuropeptides was performed in
the same culture preparations. For the experiments using
inhibitors the mRNA quantification is shown as percentage of
control. The procedure was performed for five independent
culture preparations.
Statistical analysis
All the experiments were replicated in four to five independent
culture preparations. The values in the figures are expressed as
mean 6 SEM. For the experiments involving fluoxetine and
inhibitors treatment, data were analyzed by one-way ANOVA
with post hoc test to determine significant differences between
groups. For the experiments involving neuropeptides quantifica-
tion during passages and neurospheres percentage for size
intervals, data were analyzed by two-way ANOVA with post
hoc test to determine significant differences between control and
fluoxetine groups.
Results
Hypothalamic neuroprogenitor cells and differentiated
hypothalamic neuroprogenitor cells express serotonergic
markers
Before investigating the putative actions of the selective
serotonin reuptake inhibitor fluoxetine in the proliferation/
maintenance of hypothalamic neuroprogenitor cells, we evaluated
the presence of serotonergic markers in the cultures (Figure 1).
PCR revealed the presence of mRNAs for serotonin synthesis
enzyme neuronal tryptophan hydroxylase (TPH2) (Figure 1-B),
neurogenesis associated serotonin receptor 5-HT1A (Figure 1-C)
and serotonin pre-synaptic transporter (SERT) (Figure 1-D) in
hypothalamic neuroprogenitor cells cultured as neurospheres and
after differentiation.
Fluoxetine promotes the proliferation of hypothalamic
neuroprogenitor cells
In order to evaluate the neurogenic effects of fluoxetine in
hypothalamic neuroprogenitor cells, we mimic the perinatal
exposure to this drug by incubating hypothalamic neurospheres
with fluoxetine for up to 5 weeks. In rodents, hypothalamic
neuronal precursors can be isolated from the early embryonic
period until adulthood [5,6,7]. Therefore, we obtained the
hypothalamic neurospheres from E18-19 rat embryos as previ-
ously described by our group [8]. The incubation period was
based on previous reports showing that maximal increase in
Figure 1. Presence of serotonergic markers in hypothalamic
neuroprogenitor cells. Representative gel electrophoresis with PCR
products demonstrating the presence of b-actin (A), neuronal
tryptophan hidroxylase (TPH2) (B), serotonin receptor 5-HT1A (C) and
serotonin pre-synaptic transport (SERT) (D) in hypothalamic neuropro-
genitor cells. PCR was performed in cDNA samples obtained from
hypothalamic neurospheres: (1) - P1 control; (2) P1 treated with
fluoxetine; (3) - P3 control; (4) - P3 treated with fluoxetine; (5) –
differentiated control; (6) – differentiated treated with fluoxetine; and
(+) whole adult brain (positive control). P, passage.
doi:10.1371/journal.pone.0088917.g001
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neurogenesis achieved by fluoxetine and other SSRIs occurs after
a prolonged treatment, in adult mice hippocampus [27,28].
We first observed that, morphologically, neurospheres exposed
to fluoxetine were larger than control neurospheres, as shown in
phase-contrast microscopy (Figure 2-A) and nuclear staining with
DAPI (Figure 2-B). To further evaluate this effect, we measured
the diameter of hypothalamic neurospheres throughout the
passages and compared the size distribution (Figure 2-C).
Fluoxetine drastically increased the percentage of .210 mm
diameter neurospheres at the passages P1, P2 and P4 (Figure 2-C).
Additionally, fluoxetine showed the strongest effect at the third
passage (P3) when it induced an increase in the percentage of large
neurospheres (150–210 mm and .210 mm diameter neuro-
spheres), together with a decrease in the percentage of small
neurospheres (,90 mm and 90–150 mm diameter neurospheres)
(Figure 2-Ciii). These data demonstrating an increase in the size of
neurospheres indicate that fluoxetine promotes the proliferation
and/or survival of hypothalamic neuroprogenitor cells.
To clarify this effect, we evaluated the number of Ki-67 positive
cells; Ki-67 is a commonly used proliferation marker that stains
cells in active cell cycle [4]. In P3 neurospheres (the passage when
the effect of fluoxetine on neurospheres diameter was more
evident) we observed that fluoxetine increased the immunostaining
for Ki-67 (Figure 3-A), with a 20% increase in the percentage of
Ki-67 positive cells compared to control (Figure 3-B).
Involvement of BDNF in the proliferation of
hypothalamic neuroprogenitor cells promoted by
fluoxetine
It has been reported that the activation of hippocampal
neurogenesis induced by antidepressants involves an upregulation
of BDNF (Brain-Derived Neurotrophic Factor) [29,30]. BDNF is a
neurotrophin expressed in the adult rodent hypothalamus [31]
that promotes neurogenesis in this brain region after infusion to
the third ventricle [3]. Interestingly, in our cell model, we observed
that fluoxetine significantly upregulated the levels of BDNF in P3
hypothalamic neurospheres, but not in earlier passages, with a 2-
fold increase in the BDNF mRNA when compared to control, as
shown in Figure 3-C.
The neurobiological actions of neurotrophins are mediated by a
family a tyrosine kinase receptors: TrkA, TrkB and TrkC
receptors. Therefore, to investigate the involvement of neurotro-
phins in the proliferation of hypothalamic neuroprogenitor cells
induced by fluoxetine we used K252a, a Trk receptors inhibitor.
K252a is an alkaloid extensively used as Trk receptors antagonist,
[29,32,33,34], which can block the different types of Trk receptors
and prevent the action of neurotrophins that exist in the
hypothalamic neurospheres cultures.
In our study, we quantified the number of Ki-67 positive cells
after incubation with cell proliferation inhibitor AraC or Trk
receptors inhibitor K252a, during the last 24 hours before cell
fixation. The elevated number of proliferative cells was reversed to
Figure 2. Fluoxetine increases the size of hypothalamic neurospheres. Hypothalamic neurospheres were incubated with fluoxetine (1 mM)
throughout 3 passages. Representative images of P3 hypothalamic neurospheres morphology showed by phase-contrast microscopy (A), and
nuclear staining with DAPI (white) (B). (C) Diameter distribution of hypothalamic neurospheres in passages 1 to 4. Mean 6 SEM; n = 3/4; Two-way
ANOVA; ns, p.0.05; *, p,0.05; **, p,0.01, ***, p,0.001 compared to control. P, passage. Scale bar: 100 mm.
doi:10.1371/journal.pone.0088917.g002
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control levels by incubation with AraC or K252a in fluoxetine
treated cultures (Figure 3-A and B). Both inhibitors had no effect
in the number of proliferative cells in control neurospheres
(Figure 3-B). Since Ki-67 reveals cells in active cycle at the time of
fixation, these results show that the 24 hours incubation with
inhibitors was sufficient to block the fluoxetine-induced prolifer-
ation. Moreover, the fact that 24 hours incubation with AraC is
sufficient to decrease fluoxetine-induced, but not basal, prolifer-
ation suggests that cells growing in the presence of this
antidepressant drug present higher proliferation rates and
incorporate proliferation inhibitor AraC faster than control cells.
Additionally, incubation of P3 neurospheres with AraC did not
change significantly the expression of BDNF mRNA in both
conditions (Figure S1). However, the incubation with K252a,
induced a compensatory increase in BNDF mRNA both in control
and fluoxetine P3 neurospheres (Figure S1), suggesting a
compensatory increase of BDNF expression upon the blockade
of Trk receptors.
Overall, these results show that fluoxetine promotes the
proliferation of hypothalamic neuroprogenitor cells, via a mech-
anism involving neurotrophins.
Fluoxetine upregulates the levels of orexigenic
neuropeptides, but not of anorexigenic neuropeptides,
in hypothalamic neurospheres
Proliferation changes during hypothalamic neurodevelopment
can lead to an impaired balance between neurons expressing
orexigenic and anorexigenic neuropeptides [10,11]. Since hypo-
thalamic neuroprogenitor cells obtained from rat embryos express
neuropeptides important for the regulation of food intake [8], we
used the neurospheres cell model to evaluate the effect of
fluoxetine in the mRNA expression of orexigenic (NPY and
AgRP) and anorexigenic (POMC and CART) neuropeptides
(Figure 4).
Concerning the orexigenic neuropeptides, fluoxetine signifi-
cantly increased the expression of NPY in hypothalamic neuro-
spheres, with a 1.5-fold increase in mRNA levels at P2, and a 2-
fold increase at P3 (Figure 4-A). To investigate whether the
upregulation of NPY was dependent of the proliferative effect of
fluoxetine in hypothalamic neuroprogenitor cells, we incubated P3
neurospheres with proliferation inhibitor AraC (24 h) and Trk
receptors inhibitor K252a (24 h). In fact, the NPY mRNA
returned to control levels with AraC or K252a incubation
(Figure 4-B), indicating that both proliferation and Trk receptors
mediate the upregulation of NPY levels induced by fluoxetine in
hypothalamic neuroprogenitor cells. Both inhibitors had no effect
in the NPY mRNA levels in control neurospheres (Figure 4-B).
Additionally, fluoxetine led to an earlier rise on AgRP levels,
with a 5-fold increase in the mRNA levels occurring at P1
(Figure 4-C). In control neurospheres, the 2.5-fold increase in the
expression of this neuropeptide occurred later at P2 (Figure 4-C).
In opposition, the levels of anorexigenic neuropeptides were not
different between control and fluoxetine treated neurospheres
along the passages, as shown by mRNA levels of POMC (Figure 4-
D) and CART (Figure 4-E).
All together, these data show that fluoxetine modifies the
expression levels of neuropeptides important for the regulation of
feeding and that this effect is dependent of the proliferative effect
of fluoxetine on hypothalamic neuroprogenitor cells.
Figure 3. Fluoxetine promotes the proliferation of hypothalamic neuroprogenitor cells. Hypothalamic neurospheres were incubated with
fluoxetine (1 mM) throughout 3 passages. Representative confocal photomicrographs of cell proliferation marker Ki-67 (red) (A). Fluoxetine increases
the percentage of Ki-67 positive cells and 24 hours incubation with proliferation inhibitor AraC or Trk receptors inhibitor K252a reverses this effect
(B). Fluoxetine upregulates the mRNA levels of neurotrophic factor BDNF (C). DAPI (blue), nuclear staining. Mean 6 SEM; n = 4; One-Way ANOVA (B)
and Two-Way ANOVA (C); ns, p.0.05; *, p,0.05; ***, p,0.001 compared to control; ##, p,0.01; ###, p,0.001 compared to fluoxetine. Scale bar:
50 mm. P, passage.
doi:10.1371/journal.pone.0088917.g003
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Fluoxetine inhibits the differentiation of hypothalamic
neuroprogenitor cells
To evaluate the effects of fluoxetine during the differentiation of
hypothalamic neuroprogenitor cells, we allowed the neurospheres
to differentiate for 18 days in presence or absence of fluoxetine.
After that, the differentiation profile was evaluated by quantifica-
tion of the number of mature neurons (Neu-N+ cells) and
progenitor cells (SOX-2+ cells) [35]. Hypothalamic neuroprogeni-
tor cells differentiated in the presence of fluoxetine showed a
decreased immunostaining for mature neurons marker (Figure 5-
A) with a 4562.5% reduction in the percentage of Neu-N positive
cells, compared to untreated cells (Figure 5-B). Moreover, the
number of progenitor cells (SOX-2+ cells) was robustly increased
in the cultures incubated with fluoxetine during differentiation
(Figure 5-C), with a 3.3-fold increase in the percentage of SOX-2
positive cells compared to control conditions (Figure 5-D).
Together these evidences suggest that fluoxetine inhibits the
neuronal differentiation of hypothalamic neuroprogenitor cells
and maintains their undifferentiated status.
To evaluate the contribution of neurotrophins to the mainte-
nance of hypothalamic neuroprogenitor cells in the undifferenti-
ated state we first evaluated the expression of BDNF (Figure 5-E).
The mRNA levels of BDNF were not changed in the cultures
differentiated in the presence of fluoxetine as compared to control
cultures (Figure 5-E). However, there was a compensatory increase
in the mRNA levels of BDNF after incubation with Trk receptors
inhibitor K252a for 24 hours (Figure 5-E), similar to the one
observed for the hypothalamic neurospheres.
On the other hand, the effect of fluoxetine on reducing the
number of Neu-N positive cells was partially inhibited by
incubation with Trk receptor inhibitor K252a for 24 hours
(Figure 5-B). Nevertheless, this inhibitor did not change the
number of SOX-2 positive cells (Figure 5-D).
Fluoxetine decreases the levels of abundant
neuropeptides in differentiated hypothalamic
neuroprogenitor cells
Differentiated hypothalamic neuroprogenitor cells express
neuropeptides important for the regulation of food intake,
including NPY, AgRP, POMC and CART [8]. To investigate
whether fluoxetine affects the expression of these neuropeptides,
we quantified their mRNA levels after differentiation in the
presence or absence of fluoxetine.
Hypothalamic neuroprogenitor cells differentiated in the
presence of fluoxetine showed a 54.063.3% decrease in the
NPY mRNA levels (Figure 6-A) and a 59.066.3% decrease in
the CART mRNA levels (Figure 6-D). In opposition, the mRNA
levels of AgRP (Figure 6-B) and POMC (Figure 6-C) were not
affected.
Interestingly, NPY and CART are the neuropeptides that
showed a higher enrichment during the neuronal differentiation of
hypothalamic neuroprogenitor cells, as previously reported by our
group [8]. Therefore, we can hypothesize that fluoxetine, by
decreasing the neuronal differentiation of these cells, inhibits the
elevation of abundant neuropeptides NPY and CART mRNA but
has no effect on the levels of less abundant neuropeptides AgRP
and POMC.
Additionally, hypothalamic neuroprogenitor cells were incubat-
ed with Trk receptors inhibitor K252a for 24 hours, to evaluate
the involvement of Trk receptors in the differentiation of these
cells. Incubation with K252a led to a wide increase in the levels of
neuropeptides NPY, POMC and CART, but not AgRP, that
occurred independently of fluoxetine treatment (Figure 6). There-
fore, the effect of K252a in neuropeptides levels does not seem to
be related to the blockade of Trk receptors. Other properties
of K252a, such as stabilization of calcium homeostasis and support
of neuronal survivor [36], may be associated to this increase of
neuropeptides levels.
Discussion
The present work shows that the antidepressant drug fluoxetine
promotes the proliferation and maintenance of hypothalamic
neuroprogenitor cells and, by means of this effect, changes the
expression of neuropeptides important for the regulation of
feeding. Understanding the actions of SSRIs in the embryonic
hypothalamus is of utmost importance since antidepressants
therapy is frequent among women in the perinatal period [15]
Figure 4. Fluoxetine upregulates the levels of orexigenic neuropeptides NPY and AgRP in hypothalamic neuroprogenitor cells.
Fluoxetine increases the mRNA levels of NPY during P2 and P3 (A). The 24 hours incubation with proliferation inhibitor AraC and Trk receptor
inhibitor K252a reverses the increase of NPY mRNA induced by fluoxetine (B). Fluoxetine anticipates the increase of AgRP mRNA in P1 neurospheres
(C). Fluoxetine has no effect in the mRNA levels of the anorexigenic neuropeptides: POMC (D) and CART (E). Mean6 SEM; n= 4; Two-Way ANOVA (A,
C, D, E) and One-Way ANOVA (B); ns, p.0.05; *, p,0.05; **, p,0.01; ***, p,0.001 compared to control; NS, p.0.05 compared to fluoxetine. P,
passage.
doi:10.1371/journal.pone.0088917.g004
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and energy balance alterations in newborns have been described
after maternal exposure to antidepressants [20,21,22,24].
Notably, we demonstrate that hypothalamic neuroprogenitor
cells are susceptible to SSRI exposure as shown by the presence of
serotonergic markers, including serotonin synthesis enzyme
(TPH2), pre-synaptic transporter and 5-HT1A receptor. Accord-
ingly, the 5-HT1A receptor was previously associated to the
neurogenic effect of antidepressants in the hippocampus [27,37].
Fluoxetine promotes the proliferation and maintenance
of hypothalamic neuroprogenitor cells
In this study we have investigated the neurogenic actions of
fluoxetine in hypothalamic neuroprogenitor cells cultured as
neurospheres. This model presents the limitations of an in vitro
model, particularly the possibility that the mechanisms observed
for the cell culture preparations will not be recapitulated in the
living organism. Nevertheless, the neurospheres culture model has
been extensively used by researchers for studying proliferation of
well-known neurogenic regions like the lateral ventricles and
hippocampus [38,39]. More recently, this model has been used for
investigating neurogenesis in the embryonic hypothalamus [9,10]
and adult hypothalamus [6,40,41]. Additionally, this is an
interesting model to study hypothalamic neurogenesis since
proliferation mechanisms described for hypothalamic neuro-
spheres cultures are often recapitulated in the rodent hypothala-
mus [6,40,41].
Fluoxetine promotes the proliferation and survival of new
neurons in the adult hippocampus [27,28] by increasing the
symmetric divisions of early progenitor cell [42]. However, the
possible neurogenic effect of this SSRI in the hypothalamus was
Figure 5. Fluoxetine inhibits the differentiation of hypothalamic neuroprogenitor cells. Hypothalamic neuroprogenitor cells were
differentiated for 18 days, in the presence or absence of fluoxetine (1 mM). Representative confocal photomicrographs for mature neurons marker
Neu-N (green) (A). Fluoxetine decreases the percentage of Neu-N positive cells and the incubation with Trk receptors inhibitor K252a (24 h) partially
reverses this effect (B). Representative confocal photomicrographs for the progenitor cells marker SOX-2 (green) (C). Fluoxetine increases the
percentage of SOX-2 positive cells and the incubation with K252a (24 h) does not change this effect (D). Fluoxetine does not up regulate the levels of
neurotrophic factor BDNF but incubation with K252a (24 h) results in a compensatory increase of BDNF mRNA levels (E). DAPI (blue), nuclear staining.
Mean 6 SEM; n = 4/5; One-Way ANOVA; ns, p.0.05; *, p,0.05; ***, p,0.001 compared to control; NS, p.0.05, #, p,0.05 compared to fluoxetine.
Scale bar: 50 mm.
doi:10.1371/journal.pone.0088917.g005
Figure 6. Fluoxetine decreases the levels of abundant neuro-
peptides (NPY and CART) in hypothalamic differentiated
neuroprogenitor cells. Fluoxetine decreases the mRNA levels of
neuropeptides that are abundant in differentiated hypothalamic
neuroprogenitor cultures NPY (A) and CART (D), but has no effect in
the mRNA of AgRP (B) and POMC (C). Mean 6 SEM; n= 5; One-Way
ANOVA; ns, p.0.05; *, p,0.05; **, p,0.01; ***, p,0.001 compared to
control; NS, p.0.05, #, p,0.05, ###, p,0.001 compared to fluoxetine.
doi:10.1371/journal.pone.0088917.g006
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unknown. With this work, we demonstrate that fluoxetine
stimulates the proliferation of neuroprogenitor cells obtained from
the fetal hypothalamus, and maintains the hypothalamic neuro-
progenitor cells in the undifferentiated state. Additionally, we
showed that the proliferative effect of fluoxetine in hypothalamic
neuroprogenitor cells is mediated by neurotrophins.
Furthermore, the involvement of BDNF is suggested by the data
showing an upregulation of BDNF mRNA levels in the neuro-
spheres treated with fluoxetine at P3, the passage with maximal
proliferative effect (as shown with neurospheres size). Noteworthy,
previous reports showing that the response of neuroprogenitor
cells to fluoxetine is mediated by an upregulation of BDNF levels
in the hippocampus [29,30,43] and that a chronic administration
of fluoxetine is needed to initiate the proliferation of new neurons
in the hippocampus of mice [27,28], support the role of BDNF as
mediator of fluoxetine neurogenic actions.
Moreover, BDNF is an important molecule to the cellular
physiology of the hypothalamus since it is involved in the neuronal
development and maturation of this brain region [44,45] and in
the stimulation hypothalamic neurogenesis [3]. Considering these
evidences, it is even possible that BDNF plays a role in the basal
maintenance of hypothalamic neuroprogenitor cells (although this
hypothesis was not investigated in the present study).
In opposition, the inhibition of neuronal differentiation
produced by fluoxetine does not seem to be mediated by
neurotrophins: the mRNA level of BDNF is similar in hypotha-
lamic neuroprogenitor cells differentiated in the presence or
absence of fluoxetine and Trk receptors inhibitor does not reverse
the high number of SOX-2 positive cells observed in fluoxetine-
treated cell cultures. However, the incubation with K252a
partially reversed the low number of mature neurons quantified
in cultures differentiated in the presence of this antidepressant.
Other mediators of fluoxetine neurogenic activity, such as the
recently described glial cell-derived neurotrophic factor (GDNF),
cyclin-dependent kinase inhibitor p21 and Wnt3a [29,46,47], may
be responsible for the effect observed in our study but their
evaluation was beyond the scope of this article.
Fluoxetine modifies the expression of neuropeptides that
regulate food intake
In this study, we showed that fluoxetine alters the expression
levels of neuropeptides important for the regulation of appetite,
including upregulation of orexigenic neuropeptides NPY and
AgRP, during the proliferation of hypothalamic neuroprogenitor
cells, and down regulation of abundant neuropeptides NPY and
CART, during the differentiation of these cells. Moreover, our
results suggest that the alterations of neuropeptides levels
promoted by fluoxetine are mediated by its effects in the
proliferation and maintenance of neuroprogenitor cells.
The expression of NPY (and other neuropeptides) in embryonic
mitotic cells, and in particular, in hypothalamic neuroprogenitor/
neuroprecursor cells was previously demonstrated in neurospheres
cultures [8] and mice hypothalamus [5,6]. However, the presence
of specific neuropeptides in these cells may not reflect the
acquisition of their terminal peptidergic phenotype [5], as this
dynamic process occurring during the prenatal development of
feeding circuits is not concluded until the postnatal period [48,49].
Nevertheless, it raises the possibility that factors influencing cell
fate decisions within this period can permanently affect the
hypothalamic peptidergic composition.
Therefore, changes of proliferation and neuropeptides content
in hypothalamic neuroprogenitor cells induced by fluoxetine may
influence the neuronal differentiation process. This hypothesis is in
accordance to a previous study showing that the neurogenesis of
orexigenic precursors can be altered by stimuli reaching the
hypothalamus and lead to increased density of orexigenic neurons
[11].
The involvement of neurotrophins in the effects of fluoxetine
further supports the possibility that fluoxetine modifies the
expression of neuropeptides by promoting the propagation of
hypothalamic neuroprogenitor cells. First, the most significant
increase of NPY mRNA occurs simultaneously with the BDNF
upregulation and the most robust increase in cellular proliferation.
Second, the levels of NPY mRNA return to control after
incubation with Trk receptors inhibitor, as it occurred with
proliferation inhibitor. Similarly to the data reported here, BDNF
upregulates the levels of NPY in cortical cell cultures and
hippocampal slices [50,51], as well as in the hippocampus and
cortex after continuous infusion [52,53].
Surprisingly, previous studies reporting the effects of fluoxetine
and BDNF in the adult hypothalamus show opposite evidences
from the ones reported in this work. For example, administration
of fluoxetine and other serotonergic drugs decreases the content
and release of NPY [54,55,56] and does not upregulate the levels
of BDNF [57] in the hypothalamus of adult rats.
These evidences lead us to hypothesize that the SSRI fluoxetine
has divergent actions in mature and neuroprogenitor hypotha-
lamic cells, with the neurogenic activity being more evident on this
last type of cells (and responsible for the alterations of neuropep-
tides levels observed in this study). Our hypothesis is further
supported by previous reports showing that the cognitive outcomes
of serotonin transporter blockade during development are
sometimes dramatically different from the effects during adulthood
[58].
Moreover, we can speculate that due to the reduced number of
neuroprogenitor cells in the adult hypothalamus [3], the effects of
serotonergic analogs in neuroprogenitor cells are more clearly
observed in the in vitro model described here. This hypothesis
reinforces the need of understanding the consequences of exposing
embryonic and adult hypothalamic neuroprogenitor cells to
antidepressants. In this context, the in vitro model used for the
present study can represent a valuable model to screen possible
neurogenic effects of other drugs in hypothalamic neuroprogenitor
cells.
Conclusion
The importance of adult hypothalamic neurogenesis and
plasticity to the metabolic response to dietary challenges was
recently demonstrated [4,6]. But the maternal exposure to
molecules that modify hypothalamic proliferation in the prenatal
period may compromise that neurogenic capacity in adulthood, as
demonstrated for diet lipids and hormones [10,11].
Our in vitro study shows that SSRIs antidepressants have the
potential to change the proliferation/differentiation of neuropro-
genitor cells from the embryonic hypothalamus. Although future in
vivo studies are needed, based on the presented results, we can
speculate that antidepressant drugs may be yet another contrib-
utor to impaired neurodevelopment of this key metabolism center
by increasing the pool of neuroprogenitor cells and inhibiting the
differentiation of these cells.
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Figure S1 Trk receptors inhibitor K252a upregulates
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upregulation of the mRNA levels of neurotrophic factor BDNF.
Incubation with proliferation inhibitor AraC for 24 hours does not
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